Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 5/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4075995 | 0.79 | SIGMAR1 (0.51) | SIGMAR1 | |
| SCHEMBL16836045 | 0.70 | SIGMAR1 (0.56) | SIGMAR1ADRA2A | |
| SCHEMBL28217942 | 0.69 | SIGMAR1 (1.00) | SIGMAR1KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL15160120 | 0.69 | SIGMAR1 (0.72) | SIGMAR1ADRA2A | |
| SCHEMBL2514601 | 0.68 | SIGMAR1 (0.60) | SIGMAR1 | |
| Hydrochloric Acid SCHEMBL4068594 | 0.68 | SIGMAR1 (0.49) | SIGMAR1 | |
| SCHEMBL7016275 | 0.67 | SIGMAR1 (0.72) | SIGMAR1ALDH1A1MEN1KMT2A | |
| SCHEMBL20955200 | 0.67 | SIGMAR1 (0.47) | SIGMAR1NPC1TP53KDM4EALDH1A1 | |
| SCHEMBL2911419 | 0.67 | SIGMAR1 (0.49) | SIGMAR1NPC1TP53KDM4EALDH1A1 | |
| SCHEMBL4068846 | 0.66 | SIGMAR1 (0.48) | SIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | BANYU PHARMACEUTICAL CO., LTD. | 2009-10-01 | — | — | US | disclosed |
| EP-2072519-A1 | DIARYL KETIMINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-06-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247560-A1 | Diaryl ketimine derivative | NR0B2, NR2C2, NR3C2 | SIGMAR1 1623/4885NPC1 1131/4885TP53 4644/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.